The Food and Drug Administration approved said it approved Nuvation Bio’s (NUVB) Ibtrozi, a kinase inhibitor, for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer. The prescribing information for Ibtrozi includes warnings and precautions for hepatotoxicity, interstitial lung disease/pneumonitis, QTc interval prolongation, hyperuricemia, myalgia with creatine phosphokinase elevation, skeletal fractures, and embryo-fetal toxicity.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NUVB:
- Nuvation Bio’s Strategic Positioning and Potential FDA Approval: Analyst Recommends Buy Rating
- Nuvation Bio Holds Successful Annual Meeting 2025
- Nuvation Bio’s Positive Outlook: Taletrectinib Approval and Financial Strength
- Buy Recommendation for Nuvation Bio: Promising Clinical Results and Strong Financial Position
- Nuvation Bio: Undervalued Growth Potential with Key Developments on the Horizon